| A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer A Kulkarni, V Chandrasekar, SK Natarajan, A Ramesh, P Pandey, ... Nature Biomedical Engineering, 1, 2018 | 167 | 2018 |
| Mesoporous silica nanoparticles: importance of surface modifications and its role in drug delivery SK Natarajan, S Selvaraj Rsc Advances 4 (28), 14328-14334, 2014 | 148 | 2014 |
| Reporter nanoparticle that monitors its anticancer efficacy in real time A Kulkarni, P Rao, S Natarajan, A Goldman, VS Sabbisetti, Y Khater, ... Proceedings of the National Academy of Sciences 113 (15), E2104-E2113, 2016 | 76 | 2016 |
| Glutamine Metabolism in Brain Tumors SK Natarajan, S Venneti Cancers 11 (11), 1628, 2019 | 69 | 2019 |
| Rationally designed 2-in-1 nanoparticles can overcome adaptive resistance in cancer A Goldman, A Kulkarni, M Kohandel, P Pandey, P Rao, SK Natarajan, ... ACS nano 10 (6), 5823-5834, 2016 | 69 | 2016 |
| A microfluidic platform for drug screening in a 3D cancer microenvironment HJ Pandya, K Dhingra, D Prabhakar, V Chandrasekar, SK Natarajan, ... Biosensors and Bioelectronics 94, 632-642, 2017 | 64 | 2017 |
| Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas D Pratt, SK Natarajan, A Banda, C Giannini, P Vats, C Koschmann, ... Acta neuropathologica, 1-3, 2018 | 58 | 2018 |
| Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy A Kulkarni, SK Natarajan, V Chandrasekar, PR Pandey, S Sengupta ACS nano 10 (10), 9227-9242, 2016 | 46 | 2016 |
| Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer AA Kulkarni, VE Vijaykumar, SK Natarajan, S Sengupta, VS Sabbisetti Nanomedicine: Nanotechnology, Biology and Medicine 12 (7), 1853-1861, 2016 | 33 | 2016 |
| Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas P Panwalkar, B Tamrazi, D Dang, C Chung, S Sweha, SK Natarajan, ... Science Translational Medicine 13 (614), eabc0497, 2021 | 30 | 2021 |
| Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anticancer Efficacy A Kulkarni, P Pandey, P Rao, A Mahmoud, A Goldman, V Sabbisetti, ... ACS nano 10 (9), 8154-8168, 2016 | 21 | 2016 |
| Epigenetically defined therapeutic targeting in H3. 3G34R/V high-grade gliomas SR Sweha, C Chung, SK Natarajan, P Panwalkar, M Pun, A Ghali, ... Science Translational Medicine 13 (615), eabf7860, 2021 | 20 | 2021 |
| Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor A Ramesh, SK Natarajan, D Nandi, A Kulkarni Cellular and Molecular Bioengineering, 1-17, 0 | 16 | |
| Nano-Engineered Disruption of Heat shock protein 90 (Hsp90) Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer M Smalley, SK Natarajan, J Mondal, D Goldman, B Shanthappa, ... Cancer Research, 2020 | 12 | 2020 |
| Glioblastoma stem cell HISTArionics SK Natarajan, S Venneti Cell Stem Cell 29 (11), 1509-1510, 2022 | 1 | 2022 |
| ZFTA-RELA fusion aberrantly drives glutamine metabolism in lethal pediatric ependymomas SK Natarajan, J Haggerty-Skeans, J Lum, P Narayanan, S Sweha, S Sunil, ... Cancer Research 83 (7_Supplement), 6047-6047, 2023 | | 2023 |
| Poly Combs the Immune System: PRC2 Loss in Malignant Peripheral Nerve Sheath Tumors Can Dampen Immune Responses SK Natarajan, S Venneti Cancer research 79 (13), 3172-3173, 2019 | | 2019 |
| A Meta-Analysis of H3K27M Mutations In Gliomas Demonstrates Differential Location-Dependent Prognostic Outcomes DW Pratt, SK Natarajan, A Banda, M Quezado, P Vats, C Koschmann, ... LABORATORY INVESTIGATION 98, 665-665, 2018 | | 2018 |
| Towards understanding the cellular uptake patterns of nano-particles among different immune cell lines N Ismail, A Kulkarni, S Kumar, S Sengupta Cancer Research 77 (13 Supplement), 4610-4610, 2017 | | 2017 |
| Abstract B52: 2-in-1 “sniper” nanomedicines rescue dendritic cells by two pronged inhibition of JAK2/STAT-3 and p38 MAPK pathways SK Natarajan, V Chandhrasekar, N Ismail, S Swaminathan, S Sengupta, ... Cancer Research 77 (2 Supplement), B52-B52, 2017 | | 2017 |
